Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi
<p>Abstract</p> <p>Background</p> <p>The aim of this study is to compare the effectiveness of <sup>131</sup>I therapy between three groups of DTC patients who received 30, 60 or 100 mCi for thyroid remnant ablation after total thyroidectomy and were postoper...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-11-01
|
| Series: | Thyroid Research |
| Online Access: | http://www.thyroidresearchjournal.com/content/3/1/9 |
| _version_ | 1818228975322791936 |
|---|---|
| author | Kukulska Aleksandra Krajewska Jolanta Gawkowska-Suwińska Marzena Puch Zbigniew Paliczka-Cieslik Ewa Roskosz Jozef Handkiewicz-Junak Daria Jarzab Michał Gubała Elzbieta Jarzab Barbara |
| author_facet | Kukulska Aleksandra Krajewska Jolanta Gawkowska-Suwińska Marzena Puch Zbigniew Paliczka-Cieslik Ewa Roskosz Jozef Handkiewicz-Junak Daria Jarzab Michał Gubała Elzbieta Jarzab Barbara |
| author_sort | Kukulska Aleksandra |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>The aim of this study is to compare the effectiveness of <sup>131</sup>I therapy between three groups of DTC patients who received 30, 60 or 100 mCi for thyroid remnant ablation after total thyroidectomy and were postoperatively judged with low risk of cancer recurrence.</p> <p>Methods</p> <p>The project was designed as a two-stage, prospective randomized clinical trial. In 1998-2001 in a randomized prospective study the early comparison of treatment with 30 mCi vs 60 mCi suggested the lower <sup>131</sup>I activity to be less effective, whereas in 2003-2005 the comparison between 60 vs 100 mCi showed no significant differences. The present study comprises the long-term assessment of the disease course in 3 study groups.</p> <p>Results</p> <p>A group of 309 DTC patients (285 women and 24 men) with no clinical, histopathological, sonographical or biochemical signs of persistent disease were included after total thyroidectomy and appropriate extent of neck lymph node dissection (265 with papillary and 44 with follicular thyroid cancer). For radioiodine thyroid remnant ablation, 30 mCi of <sup>131</sup>I was applied in 86 patients, whereas 60 mCi in 128 and 100 mCi in 95 patients. The median follow-up was 10 years (2-12) for subjects treated with 30 mCi and 60 mCi and 6 years (2-6) for patients treated with 100 mCi of <sup>131</sup>I. In the first evaluation, published previously, we observed that because of incomplete thyroid remnant ablation, the second <sup>131</sup>I treatment was necessary in 10% patients, without difference between groups treated with 60 and 100 mCi and in 22% patients treated with 30 mCi. All patients entered full remission. To evaluate the long-term outcome of the adjuvant <sup>131</sup>I treatment, the course of the follow-up and the most recent disease status were assessed by sonography, radiological examinations and serum Tg estimation (on LT4-suppressive treatment). Within the whole observation period local relapse was stated in 2 (2.4%), 4 (3%) and 3 (3%) patients treated with <sup>131</sup>I activities of 30 mCi, 60 mCi and 100 mCi respectively and serum Tg concentration on LT4-suppressive treatment was low, without differences between groups.</p> <p>Conclusions</p> <p>No significant differences in the 5 years efficacy of thyroid remnant radioiodine ablation using 30, 60 and 100 mCi were observed in low-risk DTC patients operated by total thyroidectomy and neck lymph node dissection. However, patients treated initially with 30 mCi, required second course of radioiodine in 22%, while this was necessary only in 13,3% and 11,2% of patients treated with 60 mCi and 100 mCi respectively.</p> |
| first_indexed | 2024-12-12T10:11:15Z |
| format | Article |
| id | doaj.art-7d10b66218a14e0fb60d2b39d88d8234 |
| institution | Directory Open Access Journal |
| issn | 1756-6614 |
| language | English |
| last_indexed | 2024-12-12T10:11:15Z |
| publishDate | 2010-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Thyroid Research |
| spelling | doaj.art-7d10b66218a14e0fb60d2b39d88d82342022-12-22T00:27:48ZengBMCThyroid Research1756-66142010-11-0131910.1186/1756-6614-3-9Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCiKukulska AleksandraKrajewska JolantaGawkowska-Suwińska MarzenaPuch ZbigniewPaliczka-Cieslik EwaRoskosz JozefHandkiewicz-Junak DariaJarzab MichałGubała ElzbietaJarzab Barbara<p>Abstract</p> <p>Background</p> <p>The aim of this study is to compare the effectiveness of <sup>131</sup>I therapy between three groups of DTC patients who received 30, 60 or 100 mCi for thyroid remnant ablation after total thyroidectomy and were postoperatively judged with low risk of cancer recurrence.</p> <p>Methods</p> <p>The project was designed as a two-stage, prospective randomized clinical trial. In 1998-2001 in a randomized prospective study the early comparison of treatment with 30 mCi vs 60 mCi suggested the lower <sup>131</sup>I activity to be less effective, whereas in 2003-2005 the comparison between 60 vs 100 mCi showed no significant differences. The present study comprises the long-term assessment of the disease course in 3 study groups.</p> <p>Results</p> <p>A group of 309 DTC patients (285 women and 24 men) with no clinical, histopathological, sonographical or biochemical signs of persistent disease were included after total thyroidectomy and appropriate extent of neck lymph node dissection (265 with papillary and 44 with follicular thyroid cancer). For radioiodine thyroid remnant ablation, 30 mCi of <sup>131</sup>I was applied in 86 patients, whereas 60 mCi in 128 and 100 mCi in 95 patients. The median follow-up was 10 years (2-12) for subjects treated with 30 mCi and 60 mCi and 6 years (2-6) for patients treated with 100 mCi of <sup>131</sup>I. In the first evaluation, published previously, we observed that because of incomplete thyroid remnant ablation, the second <sup>131</sup>I treatment was necessary in 10% patients, without difference between groups treated with 60 and 100 mCi and in 22% patients treated with 30 mCi. All patients entered full remission. To evaluate the long-term outcome of the adjuvant <sup>131</sup>I treatment, the course of the follow-up and the most recent disease status were assessed by sonography, radiological examinations and serum Tg estimation (on LT4-suppressive treatment). Within the whole observation period local relapse was stated in 2 (2.4%), 4 (3%) and 3 (3%) patients treated with <sup>131</sup>I activities of 30 mCi, 60 mCi and 100 mCi respectively and serum Tg concentration on LT4-suppressive treatment was low, without differences between groups.</p> <p>Conclusions</p> <p>No significant differences in the 5 years efficacy of thyroid remnant radioiodine ablation using 30, 60 and 100 mCi were observed in low-risk DTC patients operated by total thyroidectomy and neck lymph node dissection. However, patients treated initially with 30 mCi, required second course of radioiodine in 22%, while this was necessary only in 13,3% and 11,2% of patients treated with 60 mCi and 100 mCi respectively.</p>http://www.thyroidresearchjournal.com/content/3/1/9 |
| spellingShingle | Kukulska Aleksandra Krajewska Jolanta Gawkowska-Suwińska Marzena Puch Zbigniew Paliczka-Cieslik Ewa Roskosz Jozef Handkiewicz-Junak Daria Jarzab Michał Gubała Elzbieta Jarzab Barbara Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi Thyroid Research |
| title | Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi |
| title_full | Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi |
| title_fullStr | Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi |
| title_full_unstemmed | Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi |
| title_short | Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi |
| title_sort | radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma dtc prospective comparison of long term outcomes of treatment with 30 60 and 100 mci |
| url | http://www.thyroidresearchjournal.com/content/3/1/9 |
| work_keys_str_mv | AT kukulskaaleksandra radioiodinethyroidremnantablationinpatientswithdifferentiatedthyroidcarcinomadtcprospectivecomparisonoflongtermoutcomesoftreatmentwith3060and100mci AT krajewskajolanta radioiodinethyroidremnantablationinpatientswithdifferentiatedthyroidcarcinomadtcprospectivecomparisonoflongtermoutcomesoftreatmentwith3060and100mci AT gawkowskasuwinskamarzena radioiodinethyroidremnantablationinpatientswithdifferentiatedthyroidcarcinomadtcprospectivecomparisonoflongtermoutcomesoftreatmentwith3060and100mci AT puchzbigniew radioiodinethyroidremnantablationinpatientswithdifferentiatedthyroidcarcinomadtcprospectivecomparisonoflongtermoutcomesoftreatmentwith3060and100mci AT paliczkacieslikewa radioiodinethyroidremnantablationinpatientswithdifferentiatedthyroidcarcinomadtcprospectivecomparisonoflongtermoutcomesoftreatmentwith3060and100mci AT roskoszjozef radioiodinethyroidremnantablationinpatientswithdifferentiatedthyroidcarcinomadtcprospectivecomparisonoflongtermoutcomesoftreatmentwith3060and100mci AT handkiewiczjunakdaria radioiodinethyroidremnantablationinpatientswithdifferentiatedthyroidcarcinomadtcprospectivecomparisonoflongtermoutcomesoftreatmentwith3060and100mci AT jarzabmichał radioiodinethyroidremnantablationinpatientswithdifferentiatedthyroidcarcinomadtcprospectivecomparisonoflongtermoutcomesoftreatmentwith3060and100mci AT gubałaelzbieta radioiodinethyroidremnantablationinpatientswithdifferentiatedthyroidcarcinomadtcprospectivecomparisonoflongtermoutcomesoftreatmentwith3060and100mci AT jarzabbarbara radioiodinethyroidremnantablationinpatientswithdifferentiatedthyroidcarcinomadtcprospectivecomparisonoflongtermoutcomesoftreatmentwith3060and100mci |